Last reviewed · How we verify
Thrombosis Prevention in Heparin-Induced Thrombocytopenia
Approved treatments
- Argatroban · Hikma Pharm Co Ltd
Argatroban works by directly inhibiting the activity of thrombin, a key enzyme in the blood clotting process.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Thrombosis Prevention in Heparin-Induced Thrombocytopenia patent landscape — cliff calendar, originator estates, attackable patents
- Thrombosis Prevention in Heparin-Induced Thrombocytopenia treatment landscape brief
- Thrombosis Prevention in Heparin-Induced Thrombocytopenia treatment updates RSS
Frequently asked questions about Thrombosis Prevention in Heparin-Induced Thrombocytopenia
What drugs treat Thrombosis Prevention in Heparin-Induced Thrombocytopenia?
Tracked treatments include Argatroban.
What is the treatment for Thrombosis Prevention in Heparin-Induced Thrombocytopenia?
Standard treatment for Thrombosis Prevention in Heparin-Induced Thrombocytopenia includes Argatroban. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Thrombosis Prevention in Heparin-Induced Thrombocytopenia patent cliff · Thrombosis Prevention in Heparin-Induced Thrombocytopenia CI report
- Treatment: Argatroban · Hikma Pharm Co Ltd
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing